Feature | April 10, 2014

Ten-Year-Old Boy is Florida’s First Pediatric Patient to Receive S-ICD

April 10, 2014 — Cardiologists at Arnold Palmer Hospital for Children performed Florida’s first pediatric implant of a new device to prevent sudden cardiac arrest.

The device, called a subcutaneous defibrillator, protects patients from sudden cardiac arrest by providing an electrical impulse to muscles surrounding the heart. It is the world’s first device to provide protection from sudden cardiac arrest while not touching the heart or blood vessels.

Sudden cardiac arrest is a condition in which the heart suddenly and unexpectedly stops beating. If this happens, blood stops flowing to the brain and other vital organs. The condition usually causes death if not treated within minutes. [1]

Cardiologists at the hospital implanted the subcutaneous defibrillator into Jose Ramos, a 10-year-old Kissimmee, Fla., boy who went into sudden cardiac arrest in February 2014 and received cardiopulmonary resuscitation from his father to save his life.

“With the subcutaneous defibrillator, we now have a way to prevent sudden cardiac arrest in pediatric patients without having wires running through their veins and into the heart,” says Rodrigo Nehgme, electrophysiologist and cardiologist at Arnold Palmer Hospital. “It is a less invasive solution with fewer risks and will save the lives of young patients at risk for sudden cardiac arrest.”

The subcutaneous defibrillator is about the size of a deck of cards and is implanted just beneath the skin below the armpit. Cardiologists then run a wire, also beneath the skin, from the device to the front of the chest and up toward the neck. Whereas older technology monitored individual heartbeats, this new device actually analyzes heart rhythm and provides an electrical impulse when the heart goes into a dangerous rhythm.

Approximately 2,000 of the subcutaneous defibrillators have been implanted in the United States, with Ramos being only the fifth pediatric case.

References:

1. National Heart, Lung and Blood Institute (https://www.nhlbi.nih.gov/health/health-topics/topics/scda/)

For more information: www.arnoldpalmerhospital.com

 

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)| August 30, 2016
August 30, 2016 — Medtronic plc announced results from the...
Medtronic, Micra TPS pacemaker, transcatheter pacing system, global clinical trial, one-year results, ESC 2016
News | Pacemakers| August 29, 2016
August 29, 2016 — Medtronic plc announced new long-term results from the Medtronic Micra Transcatheter Pacing System
Merlin, Merlin@home, SJM, St. Jude Medical Merlin, cybersecurity

St. Jude Medical said recent claims of the cyber attack vulnerability of its [email protected] remote monitoring system and its implantable EP devices are not true.

Feature | EP Lab| August 29, 2016 | Dave Fornell
August 29, 2016 — Investment research firm Muddy Waters Capital released a report Aug. 25 saying it believes St.
EpiAccess System, EpiEP, Mount Sinai New York, epicardial access
News | Ablation Systems| August 22, 2016
August 22, 2016 — The Mount Sinai Hospital is the first site in the New York metropolitan area to pioneer a new appro
warfarin, long-term stability, atrial fibrillation, DCRI study, Sean Pokorney
News | Antiplatelet and Anticoagulation Therapies| August 16, 2016
August 16, 2016 — Warfarin prescribed to prevent strokes in...
Sponsored Content | Videos | Inventory Management| August 15, 2016
Pacemakers, stents and bandages — keeping tracking of what is on hand and accurately capturing charges can be a chall
News | EP Lab| August 12, 2016
August 12, 2016 — Electrophysiology ablation navigation system company Stereotaxis Inc.
Absorb, bioresorbable stent, FDA approval, FDA approves, FDA clears, most popular content, most popular stories, DAIC

The FDA clearance of the first bioresorbable stent, the Abbott Absorb, the first week of July has been the most popular story so far for all of 2016. It is the first fully dissolving stent approved for the U.S. market and many experts say this technology could be a paradigm shift in coronary and peripheral therapies in the coming years as the technology improves. 

Feature | August 05, 2016 | Dave Fornell
 
Overlay Init